Literature DB >> 8202673

[Reactivation of hepatitis B following withdrawal of chloroquine].

B Helbling1, J Reichen.   

Abstract

A severe flare-up of chronic hepatitis B infection with liver cell insufficiency has been observed in two patients after discontinuation of chloroquine administered either as malaria prophylaxis or as treatment of presumed rheumatoid arthritis. Chloroquine is known to inhibit the association of the major histocompatibility complex type II with hepatitis B virus antigens, thereby inhibiting T-cell mediated lysis of infected cells. Furthermore, it inhibits uptake of duck hepatitis B virus by duck liver cells. These in vitro studies and our clinical observations suggest that chloroquine inhibits the lysis of hepatitis B virus infected hepatocytes. Withdrawal of chloroquine in patients with chronic hepatitis B virus infection can lead to a rebound immune response manifesting as a reactivation of hepatitis B, similar to that observed after steroid withdrawal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8202673

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  4 in total

1.  Outcome in a patient with systemic lupus erythematosus and concurrent chronic hepatitis B infection.

Authors:  Lyubomir Marinchev; Krasimir Antonov; Veneta Peytcheva; Zlatimir Kolarov
Journal:  BMJ Case Rep       Date:  2010-03-26

Review 2.  Treatment of rheumatic diseases and hepatitis B virus coinfection.

Authors:  Anna Felis-Giemza; Marzena Olesińska; Katarzyna Świerkocka; Ewa Więsik-Szewczyk; Ewa Haładyj
Journal:  Rheumatol Int       Date:  2014-12-31       Impact factor: 2.631

Review 3.  What would be the impact of COVID-19 on liver function of a patient with chronic hepatitis B? About a case and literature review.

Authors:  Khoury M'bodj; Hakima Abid; Najdi Adil; Mohammed El Abkari; Nourdin Aqodad
Journal:  Pan Afr Med J       Date:  2021-03-01

Review 4.  Isolated Anti-HBc: Significance and Management.

Authors:  Florian Moretto; François-Xavier Catherine; Clémentine Esteve; Mathieu Blot; Lionel Piroth
Journal:  J Clin Med       Date:  2020-01-11       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.